All News

5 April 2011

ImmunoGen, Inc. Announces First Data for Its IMGN529 Product Candidate for Non-Hodgkin’s LymphomaAntibodies

4 April 2011

ImmunoGen, Inc. Announces First Data for its Novel Therapeutic for Ovarian Cancer and Other CarcinomasAntibodies

4 April 2011

Peregrine Presents Phase Ib HCV/HIV Data on Single-Agent Bavituximab at EASLAntibodies

1 April 2011

Neogenix Oncology Novel Therapeutic Antibody, NEO-101 (Ensituximab) Data to Be Presented at AACR’s 2011 Annual SymposiumAntibodies

31 March 2011

Glenmark Announces the Discovery and Initiation of IND Enabling Studies of a Novel Biologics Entity, GBR 401, Targeting Lymphomas and Leukemia’s of B-Cell OriginAntibodies

30 March 2011

Erbitux Indication Extension Submitted for 1st-Line Advanced or Metastatic NSCLC in the EUAntibodies

28 March 2011

Ablynx Initiates Phase I/II Trial for Alx-0061 (Anti-Il-6R) in Patients With Rheumatoid ArthritisAntibodies

25 March 2011

Second Lucentis Phase III Study Meets Primary Endpoint for Improved Vision in Patients with Diabetic Macular Edema (DME)Antibodies

25 March 2011

FDA approves new treatment for a type of late-stage skin cancerAntibodies

24 March 2011

Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal TrialAntibodies

24 March 2011

Treatment With Prolia (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to AlendronateAntibodies

23 March 2011

Biotest: Monoclonal antibody BT-061 in combination with methotrexate demonstrates good efficacy in Rheumatoid ArthritisAntibodies

23 March 2011

XOMA 052 Phase 2b Top Line Results: Glucose Control Not Demonstrated, Positive Anti-inflammatory Effect, Cardiovascular Biomarker and Lipid Improvement and Safety ConfirmedAntibodies

23 March 2011

KaloBios Initiates Phase 1 Clinical Trial of KB004 in EphA3-Expressing Hematologic MalignanciesAntibodies

22 March 2011

Study Demonstrates Relationship Between Subcutaneous IgG (SCIg) Dosage and Clinical Outcomes With Hizentra Treatment in Patients With Primary ImmunodeficienciesAntibodies

22 March 2011

Phase III Study of Investigational Compound Ipilimumab Achieves Primary Endpoint of Improvement in Overall Survival in Previously-Untreated Patients with Metastatic MelanomaAntibodies

22 March 2011

Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with AbbottAntibodies

22 March 2011

FDA Accepts for Review Spectrum Pharmaceuticals’ ZEVALIN Submission for the Removal of the BioscanAntibodies

21 March 2011

NasVax Announces the Success of a Phase 2a Clinical Trial of a New Oral Immunotherapy for Fatty Liver DiseaseAntibodies

18 March 2011

Amgen Statement on CHMP Opinion on Vectibix (Panitumumab) Use With Chemotherapy in Metastatic Colorectal CancerAntibodies

17 March 2011

Human Genome Sciences and FivePrime Therapeutics Announce Development and Commercialization Agreement for Novel Anti-Cancer DrugAntibodies

16 March 2011

MorphoSys Signs Manufacturing Agreement with Boehringer IngelheimAntibodies

15 March 2011

Seattle Genetics and Millennium Expand Antibody-Drug Conjugate CollaborationAntibodies

14 March 2011

BioInvent International AB: First Patient Dosed in Phase II Clinical Trial for Novel Cardiovascular Drug, BI-204Antibodies

14 March 2011

Apexigen Announces the Filing by its Partner, Simcere Pharmaceutical Group, of First INDAntibodies

11 March 2011

Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung CancerAntibodies

11 March 2011

Tolerx and GlaxoSmithKline Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Primary EndpointAntibodies

10 March 2011

Santarus Initiates Phase I Clinical Study with SAN-300Antibodies

10 March 2011

Human Genome Sciences and GlaxoSmithKline Announce FDA Approval of BENLYSTA (Belimumab) for Treatment of Systemic Lupus ErythematosusAntibodies

10 March 2011

Phase III Study of Lucentis Showed Rapid Vision Improvements Sustained for Two Years in Patients with Diabetic Macular EdemaAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

EpCAM-Targeted Antibodies Pipeline Review

Ustekinumab (Stelara) Biosimilars Pipeline Review

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

GPC3-Targeted Immunotherapy Pipeline Review